TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Which is the Best Dose of Dysport in Helping With Hip Pain for Children With Cerebral Palsy?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female aged between 4 and 16 years (inclusive).~* Diagnosis of cerebral palsy.~* Presence of clinical bilateral hip pain (of at least 6 months duration) due to cerebral palsy as defined by the child/young person and/or parents.~* Paediatric Pain Profile score of 25 or greater.~Exclusion Criteria:~* Prior treatment with Botulinum toxin (any serotype, administered anywhere in the body) within 4 months prior to Screening.~* Planned or anticipated requirement for surgery during the study period.~* History of hypersensitivity to the investigational drug or any of its excipients.~* Likely to require treatment during the study with drugs that are not permitted by the study protocol or that in the opinion of the Investigator may interfere with the evaluation of the efficacy or safety of the study medication.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- Dysport 5 units (Type: EXPERIMENTAL): None
- Dysport 10 units (Type: EXPERIMENTAL): None
- Dysport 15 units (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Trial on SBRT Versus MWA for Inoperable Colorectal Liver Metastases (CLM)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>18 years~* Karnofsky index \>70%~* Histological proven adenocarcinoma of the colon or rectum with radiological (by CT- or MRI) or histological-/cytological verified liver metastases.~* Metastases must be visible on diagnostic- and dose planning CT scans and on ultrasonography.~* The patient should not be suitable for surgical resection due to technical or patient-related conditions. Resectability must be judged by a trained hepatobiliary surgeon and discussed in a multidisciplinary team meeting.~* Presence of 1-3 lesions .~* Diameter ≤ 40 mm.~* All tumors should be feasible for treatment with each of the two modalities, SBRT and MWA~* Adequate liver function: bilirubin \<1.5 mg/dl, alb\> 3.5g/dl, normal PT/PTT except if the patient uses anticoagulants, liver enzymes\<3 times upper limit of normal. No ascites.~* Renal function must be adequate for infusion of iv. contrast for CT-scan.~* Adequate bone marrow function: Hbg³8 g/dl, platelets³100.000 and leucocytes ³2.000/ml.~* Informed consent.~* Extrahepatic disease stable or in response after CT~* No previous abdominal radiation therapy (RT)~Exclusion Criteria:~* Uncontrolled primary tumor or extrahepatic disease~* Previous abdominal radiation therapy (RT) or other local conservative treatment on lesion target.~* Pregnant or breastfeeding patients.~* Prior malignancy within the last five years (except adequately treated basal cell carcinoma of the skin or in situ carcinoma of the skin or in situ carcinoma of the cervix, surgically cured, or localized prostate cancer without evidence of biochemical progression).~* Previous inclusion in this study.~* Underlying liver cirrhosis (Child-Pugh grade B or C).~* Ascites and/or relevant intra-hepatic biliary tract dilatation.~* Mental conditions rendering the patient incapable to understand the nature, scope, and consequences of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Stereotactic body radiation therapy (Type: ACTIVE_COMPARATOR): Patients are treated with Stereotactic Body Radiation Therapy, a methodology for delivering a conformal high dose of radiation to the tumor and a minimal dose to surrounding critical tissues, with a hypofractionation schedule.
- Microwave Ablation (Type: ACTIVE_COMPARATOR): Patients are treated with Microwave Ablation,a newer technology that utilizes high-frequency electromagnetic radiation to create thermal damage and coagulation necrosis.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Sublingual Methadone for the Management of Cancer-related Breakthrough Pain in Outpatients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pain due to cancer or its treatment; controlled baseline pain;~* episodes of breakthrough pain every day that are 4/10 in severity or greater, ;~* ast 10 minutes or longer, and~* are responsive to short acting oral opioids such as morphine or hydromorphone;~* are able to hole a volume of 1.0cc of water under the tongue for a 5-minute period; are able to provide written informed consent;~* are able to fill out the study forms~Exclusion Criteria:~* Severe underlying respiratory disease such that an investigator is wary about the risk of respiratory failure from modest doses of opioid;~* prior sensitivity to methadone;~* currently are being administered methadone;~* have breakthrough pain that in the opinion of the investigator is likely to change within the next seven days (recent or imminent radiation therapy to the main site of pain,~* new chemotherapy or use of an injectable bisphosphonate likely to alter the pain, new use corticosteroids within the past week with a corresponding change in pain, or other interventions judged likely to alter pain);~* are clinically unstable or have a life expectancy of less than one month making completion of the trial unlikely

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pharmacokinetic (Type: EXPERIMENTAL): One episode of breakthrough pain was to be evaluated per patient. Clinical status and bloodwork was evaluated prior to entering into this phase of the trial, and patients were eligible if bloodwork demonstrated a HgB of \>90 g/L with no concurrent bleeding. A peripheral intravenous catheter was inserted and saline locked. When breakthrough pain was experienced, methadone was administered, and the patient completed a pain intensity numeric rating scale at time 0 and every 10 minutes for one hour. A 10 cc specimen of blood was collected prior to administration of methadone, and again every 10 minutes for one hour. Blood was collected without anticoagulant, allowed to clot, separated by centrifugation, and serum samples flash frozen. Serum methadone levels were quantified by LC/MS/MS with comparison to isotopically labeled internal standards

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Perioperative Aspirin Usage Survey

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Members of the American College of Surgeons~Exclusion Criteria:~* None

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- American College of Surgeons members (Type: None): Survey participants

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: The Cooling And Surviving Septic Shock Study (CASS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Aged \> 50 years of age.~2. Severe sepsis /septic shock = SIRS + suspected infection+hypotension Mean Arterial Blood Pressure (MAP) \<70 mmHg,~3. Admitted to the participating intensive care units (ICU)~4. Indication for intubation~5. Possibility of inclusion within 6 hours after septic shock/severe sepsis is diagnosed in the ICU. Patients admitted with septic shock/severe sepsis should be included within 6 hours after admission. If a patient is not included within this period, that patient cannot be included within the same hospitalization.~6. The patient must have an expected stay in the ICU of more than 24 hours. Anticipated death within 24 hours after admission to the ICU does not exclude participation; however no decision of reduction of treatment level must have been taken. During this time period, probability that the patient is discharged to a floor department must not be likely (\<10% probability).~Exclusion Criteria:~1. Patients are pregnant or breast feeding~2. The findings of the initial screening, shows that the patient has a bleeding disorder and/or the patient has an uncontrollable bleeding and /or surgery within the last 24 hours~3. Persons who are detained under the Act on the use of coercion in psychiatry

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Mild induced hypothermia (Type: EXPERIMENTAL): Induced hypothermia to 32-34 degrees Celsius (90 - 93 degrees Fahrenheit)
- Fever Respect (Type: NO_INTERVENTION): Standard of care septic shock therapy according to Surviving Sepsis Campaign guidelines

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trials With a Local Anesthetic Lozenge for the Treatment of Chronic Oral Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with burning mouth syndrome, Sjögrens syndrome or lichen planus~* All fertile women need to use save contraception~* Age between 18 and 75 years~* Able to speak, read and understand the danish language~* Must be informed orally and release a written consent and a signed authorization statement~Exclusion Criteria:~* Pregnant or breastfeeding women~* Known allergy to bupivacaine or other local anesthetics of the amide type~* Active infection which requires antibiotic treatment~* Patients in immune suppressive treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo lozenge (Type: PLACEBO_COMPARATOR): The patients will be randomized to start two weeks treatment with either a bupivacaine lozenge or a placebo lozenge (taken three times a day). The two weeks treatment is followed by a week without treatment. Afterwards they start another two weeks treatment with the opposite type of lozenge from the first treatment period.
- Bupivacaine lozenge (Type: ACTIVE_COMPARATOR): The patient will be randomized to start two weeks treatment with either a bupivacaine lozenge or a placebo lozenge (taken three times a day). The two weeks treatment is followed by a week without treatment. Afterwards the patient starts another two weeks treatment with the opposite type of lozenge from the first treatment period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Nitric Oxide for Inhalation in Right Ventricular Infarction Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Acute inferior mycardial infarction (defined as an episode of chest pain lasting \>30 minutes and electrocardiographic evidence of 1 mm or greater ST elevation in inferior leads) within the past 72 hours.~* Invasive hemodynamic evidence of hemodynamically-significant RV dysfunction, defined as the presence of all the following: systemic venous congestion (mean RA pressure \> 10mmHg), the ratio of RA/PCW pressure 0.75 or greater, a low cardiac output as determined by Fick or Thermodilution (TD) technique (cardiac index \< 2.5 l/min/m2), systolic systemic arterial blood pressure of 90mmHg or less or requiring vasopressor or mechanical support to maintain systolic pressure \> 90mmHg. Patients with a PCWP of 14mmHg or less should receive intravascular volume repletion until their PCWP is \> 14mmHg.~* Coronary angiography revealing either an occlusion of the RCA proximal to any RV marginal branch or evidence of diminished flow to RV marginal branches of the RCA.~* If patient undergoes coronary revascularization, there must be evidence of unsuccessful right ventricular reperfusion (lack of restoration of TIMI grade III flow in the distal RCA and \> 1mm RV marginal branches) or evidence of hemodynamically significant RVI must persist for greater than 1 hour after successful revascularization.~* Age 18 years or greater~Exclusion Criteria:~* PCW 25mmHg or greater or mechanical complications of myocardial infarction requiring surgical correction.~* Severe LV systolic dysfunction as determined by the principal investigator. Unprotected left main coronary stenosis \> 50%.~* Pulmonary infiltrates consistent with pulonary edema on chest X-ray (if chest X-ray is clinically indicated).~* Evidence of shock-related end-organ damage, including creatinine 3.0 or greater, metabolic acidosis (pH 7.1 or less) and not corrected by 100 ml NaHCO3 (1mEq/ml), disseminated intravascular coagulation, or clinical evidence of diffuse brain injury.~* Previous history of severe pericardial, congenital, or valvular heart disease.~* Refractory hemodynamically significant arrhythmia.~* Presence of pneumonia, adult respiratory distress syndrome, or sepsis.~* Prior history of pulmonary disease requiring chronic oxygen therapy.~* Pregnancy~* Use of investigational drugs or device within the 30 days prior to enrollment to the study.~* Uncontrolled active bleeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): inhaled nitric oxide at 40 or 80ppm
- 2 (Type: PLACEBO_COMPARATOR): inhaled nitrogen at either 40 or 80ppm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Molecular Imaging of Inflammation With 18F-PBR06 to Identify Unstable Carotid Plaques in Patients With Stroke

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Man with transient ischemic attack or recent ischemic stroke (\<15j) in the carotid territory, confirmed by MRI~* Man with carotid stenosis\> 50% on the side of stroke~* Male candidate for carotid endarterectomy~* Subject affiliated or beneficiary of a social security scheme~* Informed written consent~Exclusion Criteria:~* Women~* Chronic inflammatory disease in progress (cancer, vasculitis, ...)~* Patient with infection within 7 days~* A person placed under judicial protection, guardianship~* Incapable of giving consent~* Low affinity binder for TSPO

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental arm (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study To Evaluate The Safety Of Voriconazole As Treatment Of Invasive Aspergillosis (Fungal Infection) And Other Rare Molds In Children

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Immunocompromised with clinically compatible illness.~* Diagnosis of proven or probable or possible Invasive Aspergillosis (based on a modified version of the revised EORTC/MSG consensus definitions).~* Diagnosis of infection due to Scedosporium or Fusarium species.~* Male and female from 2 to 17 years of age.~* Females with childbearing potential must have negative pregnancy test and be using appropriate contraception.~Exclusion Criteria:~* Allergy or hypersensitivity to the azole drugs.~* Female subjects who are pregnant or lactating.~* Patients who received more than four days of antifungal drugs to treat the current episode of invasive aspergillosis or rare mold infection.~* Received within 24 hours prior to enrollment drugs that may cause QT interval prolongation.~* Significant liver, kidney or heart dysfunction.~* Not expected to survive for at least 5 days.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Children from 2 to 17 years who have possible, probable or proven invasive aspergillosis, or other rare mold infection (eg, Scedosporium and Fusarium).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: BE Smokefree: Behavioral Economics Incentives to Engage Adolescents in Smoking Cessation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adolescents (aged 14-21 years), male or female, who speak English, screen positive for tobacco use (defined as having smoked cigarette(s) and/or used an e-cigarette product on at least 1 day during the 30 days before the clinical encounter) during their routine well child or acute visit, are interested in quitting, have a smart phone, and provide assent to participate.~Exclusion Criteria:~* Subjects that do not meet all of the inclusion criteria will not be enrolled.

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: 21 Years
- Healthy Volunteers: t

Study Arms:
- Quitline Incentive (Type: EXPERIMENTAL): The incentive structure emphasizes engaging with the Quitline Delivered Treatment, with an additional smaller payment for tobacco cessation. Each adolescent can receive compensation for enrolling in the Quitline, for maintaining involvement in the Quitline program (per call for up to 5 calls), and, for those reporting abstinence, for submitting the cotinine swab and for confirmed quitting (negative salivary cotinine). Study procedures, payments and reminders are managed through the Way to Health (WTH) platform.
- Tobacco Cessation Incentive (Type: EXPERIMENTAL): The incentive structure emphasizes quitting regardless of engagement with the Quitline Delivered Treatment (though the Quitline will be presented as a helpful tool). Each adolescent will receive compensation for enrolling in the Quitline and, for those reporting abstinence, compensation for submitting the cotinine swab and for confirmed quitting (negative salivary cotinine). Study procedures, payments and reminders are managed through the WTH platform.
- No Financial Incentive (Type: PLACEBO_COMPARATOR): No financial incentive to engage in Quitline Delivered Treatment or report abstinence. Study procedures and reminders are managed through the WTH platform.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Arthroplasty Specimens for Osteoarthritis of the Knee and Hip

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Previously randomized to R475-PN-1523 (NCT02683239), R475-OA-1611 (NCT03161093), or R475-OA-1688 (NCT03304379) and received at least 1 dose of study drug~* Notified the site that they are planning a knee or hip arthroplasty during the parent study between randomization and 24 weeks after the last dose of subcutaneous (SC) study drug~* Patient's surgeon/pathologist is willing to coordinate with the site regarding preparation, storage, and shipping of joint tissue samples collected during arthroplasty surgery~Exclusion Criteria:~* None~Note: Other protocol Inclusion criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Knee or Hip Joint Arthroplasty (Type: OTHER): Patients with OA of the knee or hip who are participating in an ongoing fasinumab phase 3 parent study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues